To determine predictors of serious adverse events (SAEs) involving syncope, hypotension, and falls, with particular attention to age, in the Systolic Blood Pressure Intervention Trial. DESIGN: Randomized clinical trial. SETTING: Academic and private practices across the United States (N 5 102). PARTICIPANTS: Adults aged 50 and older with a systolic blood pressure (SBP) of 130 to 180 mmHg at high risk of cardiovascular disease events, but without diabetes, history of stroke, symptomatic heart failure or ejection fraction less than 35%, dementia, or standing SBP less than 110 mmHg (N 5 9,361). INTERVENTION: Treatment of SBP to a goal of less than 120 mmHg or 140 mmHg. MEASUREMENTS: Outcomes were SAEs involving syncope, hypotension, and falls. Predictors were treatment assignment, demographic characteristics, comorbidities, baseline measurements, and baseline use of cardiovascular medications. RESULTS: One hundred seventy-two (1.8%) participants had SAEs involving syncope, 155 (1.6%) hypotension, and 203 (2.2%) falls. Randomization to intensive SBP control was associated with greater risk of an SAE involving hypotension (hazard ratio (HR) 5 1.67, 95% confidence interval (CI) 5 1.21-2.32, P 5 .002), and possibly syncope (HR 5 1.32, 95% CI 5 0.98-1.79, P 5 .07), but not falls (HR 5 0.98, 95% CI 5 0.75-1.29, P 5 .90). Risk of all three outcomes was higher for participants with chronic kidney disease or frailty. Older age was also associated with greater risk of syncope, hypotension, and falls, but there was no age-by-treatment interaction for any of the SAE outcomes. CONCLUSIONS: Participants randomized to intensive SBP control had greater risk of hypotension and possibly syncope, but not falls. The greater risk of developing these events associated with intensive treatment did not vary according to age. J Am Geriatr Soc 66:679-686, 2018.
despite multiple randomized clinical trials finding that those who are treated have lower cardiovascular morbidity and mortality. 2 Epidemiological studies have linked hypertension treatment with greater risk of adverse events, such as syncope and injurious falls. [3] [4] [5] Conceivably because fall-related injuries, especially fractures, are costly and a significant source of disability and mortality in older adults, [6] [7] [8] greater risk of falls has been a salient argument against intensive blood pressure control-despite conflicting data. 3, 4, 9, 10 The Systolic Blood Pressure Intervention Trial (SPRINT) showed that randomization to a systolic BP (SBP) treatment goal of less than 120 mmHg resulted in significantly fewer cardiovascular events and lower allcause mortality than a SBP treatment goal of less than 140 mmHg, 11 even in individuals aged 75 and older. 12 Although the overall number of serious adverse events (SAEs) was similar between the intensive and standard treatment groups, some have argued that the harms may have outweighed the benefits because there were more SAEs in the intensive arm for conditions expected to be related to intensive BP lowering, such as hypotension, electrolyte abnormalities, and acute kidney injury. 13 We more closely examined the risk of intensive BP treatment in SPRINT on SAEs involving three conceptually related adverse events (syncope, hypotension, falls), especially in participants aged 75 and older, because clinicians are most concerned about potential risks in older adults. To assist clinicians in making more informed, individualized decisions with patients when contemplating whether to treat to a SBP goal of less than 120 mmHg, we addressed these questions: What are the baseline risk factors for an SAE involving syncope, hypotension, and falls? Does the intensive BP goal result in greater risk of an SAE involving syncope, hypotension, or fall for individuals aged 75 and older than for those younger than 75?
METHODS

Participants and Intervention
The SPRINT Trial enrolled 9,361 participants with hypertension at 102 sites across the United States (including Puerto Rico) between November 2010 and March 2013. Participants were randomly assigned to intensive (SBP goal <120 mmHg) or standard (SBP <140 mmHg) BP control. Investigators chose from a formulary of study BP medications to achieve the targeted goal and could prescribe other medications as needed or according to participant preference. The main entry criteria for the trial were age 50 and older, SBP from 130 to 180 mmHg, and elevated risk of cardiovascular events. Participants with diabetes, history of stroke, symptomatic congestive heart failure or ejection fraction less than 35%, dementia, or standing SBP less than 110 mm Hg were excluded. Details of the inclusion criteria and intervention have been previously published. 11, 14 The intervention was stopped early, after a median follow-up of 3.26 years, because of benefit in the primary outcome (composite of myocardial infarction, acute coronary syndrome, stroke, acute decompensated heart failure, or death from cardiovascular causes) for the intensive treatment arm. 11 Institutional review boards at all sites reviewed and approved the study protocol, and all participants provided written informed consent.
Collection of Information on SAEs
Site staff asked participants about SAEs at quarterly study visits using a standardized data collection form. Site staff may have also learned about SAEs at as-needed visits or in other ways, such as participant-initiated contact, investigator involvement in participant care, or electronic medical record notifications. SAEs were defined as medical events that were fatal or life threatening, resulted in significant or persistent disability, required hospitalization, or investigators judged to represent significant hazards or harm to the participant that might require intervention to prevent an event listed above. Syncope, hypotension, and injurious falls were prespecified as safety events of interest. Ninetyfive percent of SAEs related to syncope, hypotension, or falls involved hospitalization.
Classification of SAEs and Outcomes
The Medical Dictionary for Regulatory Activities (Med-DRA) version 14.0 was used to classify the SAEs. MedDRA V R is the international medical terminology developed under the auspices of the International Conference on Harmonisation of Techincal Requirements for Registration of Pharmaceuiticals for Human Use (ICH). SPRINT safety officers (KMS, MFL, DMF) at the coordinating center reviewed all SAEs of interest, including the site narrative of the event, the hospital admission history and physical, and the discharge summary. SAEs were coded at the preferred term level; up to three preferred terms were assigned for each SAE using all information available but prioritizing hospital discharge diagnoses with a focus on reasons for admission. We then developed SPRINTspecific Standardized MedDRA Queries for syncope, hypotension, and falls to capture various preferred terms under each heading. Hypotension, including orthostatic hypotension, was coded when symptomatic low BP (without specific BP cut-offs) was mentioned in the admission history and physical or discharge summary as a reason for admission. Because these were hospital admissions, SPRINT research site staff were not able to confirm hypotension using a study-measured blood pressure. Incidentally noted low BP without symptoms was not coded as an SAE involving hypotension. Syncope was defined as a sudden temporary loss of consciousness. Presyncope or feeling faint or dizzy was not included as a syncopal event. A fall was defined as a sudden, unintentional change in position in which the participant came to rest on the ground, floor, or a lower level not as the result of syncope or overwhelming external force. A fall due to syncope was not counted as a fall, because syncope was captured separately. For descriptive purposes only, we describe fallrelated injuries in five groups: major fracture, defined as large bone fracture or fracture requiring surgical intervention; minor fracture (digits, ribs, nose, nonoperative vertebral compression fracture); intracranial hemorrhage; soft tissue injury, including hematomas, lacerations, sprains, ligamentous injuries, and joint dislocations; and no identifiable injury but admitted to the hospital after a fall.
Covariates of Interest
Baseline characteristics, assessed before any study-related treatment began, were considered as possible risk factors for syncope, hypotension, and falls. Demographic characteristics included self-reported age (modeled as <75, 75-84, 85 and separately as a continuous variable), education (12 vs >12 years), sex, and race (white, black, other). Health-related factors included known cardiovascular disease, chronic kidney disease (estimated glomerular filtration rate 20-59 mL=min), body mass index (<25.0, 25.0-29.9, 30.0 kg=m 2 ), frailty (frailty index >0.21), 15 and alcohol use (nondrinker, light to moderate, heavy (2 drinks=d). Baseline cardiovascular medications of interest were nitrates, diuretics, beta-blockers, calcium channel blockers (dihydropyridine and nondihydropyridine), angiotensinconverting enzyme inhibitors, angiotensin receptor blockers, alpha-blockers, digoxin, and number of BP medications before randomization (0, 1-2, 3). Participants selfreported their adherence to BP medications at baseline. Poor adherence was defined as a score of 6 or less on the 8-item Morisky Medication Adherence Scale. [16] [17] [18] Sitting and standing BP were measured at the baseline visit. Orthostatic hypotension was defined as a drop in SBP of 20 mmHg or more or diastolic BP of 10 mmHg or more 1 minute after standing. Participants were asked during the standing BP measure whether they felt dizzy, regardless of whether their BP had changed. Other baseline measures of interest included baseline BP, heart rate, and gait speed (usual walking speed over 4 m, measured in participants aged 75).
Statistical Methods
All data presented involve contacts or events occurring on or before August 20, 2015 , and are based on a January 31, 2016, data freeze. This data set excludes 18 syncope, 24 hypotension, and 19 fall SAEs reported previously 11 that were reclassified after final review of clinical data. We also included 3 syncope, 3 hypotension, and 7 fall SAEs occurring before August 20, 2015 , that were not previously reported.
Data are presented as counts and percentages or means 6 standard deviations unless otherwise noted. We used cumulative incidence plots to examine time until first occurrence of an SAE involving syncope, hypotension, or fall according to treatment group and proportional hazards analyses to estimate effects of baseline characteristics on time to first SAE. Separate proportional hazard models were fit for the three SAEs of interest. For each type of SAE, initial analyses examined covariates one at a time. Categorical covariates were modeled relative to a reference category, using the Wald chi-square test to test for differences between categories. Continuous covariates were modeled per standard deviation unit to facilitate comparisons. We then fit a series of multivariate models for each type of SAE. For forest plots, we first fit a model containing only age category, randomized treatment group, and their interaction. Then we fit a sequence of three models sequentially, adding baseline covariates selected because of their known or likely association with hypertension treatment or one of the three outcomes of interest. Model 1 included randomized treatment group, age category, sex, race, and education; model 2 included these factors plus health conditions (cardiovascular disease, chronic kidney disease, body mass index category, alcohol use, frailty); and model 3 included all previous covariates plus baseline measurements (SBP; heart rate; measured orthostatic hypotension; dizziness; number of antihypertensive medications; baseline use of nitrates, diuretics, beta blockers, calcium channel blockers (dihydropyridine and non-dihydropyridine), angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, alpha blockers, digoxin). For each model, participants with missing data for any covariates used in that model were excluded. The models were fit separately for each SAE type and with and without the 2-way interaction between age category and randomized treatment. Participants aged <75 years versus those 75 years and older were prespecified subgroups of the SPRINT Trial, but we modeled age as younger than 75, 75 to 84, and 85 and older to inform readers about the risks in the oldest adults. We also examined age as a continuous variable, repeating each of the models as described above.
Standard diagnostic procedures were run to examine model assumptions; no important violations were identified. All P-values were two-sided; no adjustments were made for multiple comparisons. All analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, NC).
RESULTS
We identified SAEs involving syncope in 172 participants during the trial (1.8%), hypotension in 155 (1.7%), and 2%) . Three of these participants experienced all three types of events during the trial, seven experienced syncope and falls, eight experienced hypotension and falls, and 35 experienced hypotension and syncope. The cumulative incidence of SAEs involving syncope, hypotension, and falls over time is shown according to treatment group in Figure 1 . The largest difference between treatment groups was for participants with hypotension events, for whom the two curves began to diverge at approximately 6 months and continued to separate through at least 4 years (hazard ratio (HR) 5 1.67, P 5 .002). Differences were similar, but smaller and not statistically significant, for syncope (HR 5 1.32, P 5 .07). There was no difference between groups in cumulative incidence of SAEs for falls (HR 5 0.98, P 5 .90).
Of the 203 SAEs for falls, 74% were injurious falls: 84 (41.4%) resulted in a major fracture, 18 (8.9%) in a minor fracture, and 34 (16.7%) in a soft tissue injury. Intracranial hemorrhage occurred in 15 falls (7.4%), three of which also had a major fracture. Fifty-two (25.6%) falls had no identifiable injury but nonetheless resulted in a hospital admission and thus met criteria for an SAE. Two-thirds of the falls without injury had medical reasons for admission that may have caused or contributed to the fall, such as infection, cancer, and altered mental status. Similarly, in 46.5% of SAEs involving hypotension, something other than hypotension was the primary reason for admission (e.g., gastroenteritis, other infections, sepsis). In the remaining 84 SAEs involving hypotension (54.2%), in which hypotension was listed as the primary reason for admission, it is likely that dehydration or another medical event (e.g. atrial flutter) caused the hypotension in 14.5% of cases.
Univariate relationships between baseline characteristics and the three types of SAEs are shown in Table 1 , with additional details in Supplemental Table S1 . (HR 5 1.01, P 5 .99), or hypotension (HR 5 1.62, P 5 .14). Older age was associated with greater risk of syncope, hypotension, and falls, but there was no evidence of an age-by-randomized group interaction for any of the 3 SAE types (Figure 2 ). Table 2 shows adjusted results for age-by-treatment arm interactions in successively more comprehensive models. Older age remained an important predictor of SAE for syncope and falls but not hypotension, even after adjustment for baseline potential confounders and in spite of increasing loss of sample size due to missing covariates. In all models, treatment assignment remains an important predictor of hypotension. The intervention effect on syncope is equivocal in Model 1 and is further attenuated after controlling for health conditions and baseline factors. For falls, we found no intervention effect in any model. There was no evidence that the effect of treatment differed according to age for any of the 3 conditions whether age was treated as a categorical or continuous variable (Table 2 interaction between treatment and age). Although whether baseline orthostatic hypotension or frailty modified the relationship between treatment assignment and the three SAE outcomes was not a focus of this study, it was also examined. There was no evidence of a two-way interaction between treatment group and orthostatic hypotension or frailty for any of the three outcomes (P > .7 in all cases). In addition, because we did not count an SAE involving a fall that resulted from syncope as a fall (but rather as syncope because nearly all cases of syncope will result in a fall), some may be interested in the results of a composite outcome that combines SAEs involving falls and syncope. These results are presented in Supplemental Table S2 and do not substantively change our conclusions.
DISCUSSION
In SPRINT, randomization to intensive BP control was associated with greater risk of an SAE involving hypotension and possibly syncope, but not falls. These results are qualitatively similar to the primary results of SPRINT, even when combining SAEs with emergency department visits (syncope: HR 5 1.44, P 5 .003), hypotension: HR 5 1.70, P < .001, falls: HR 5 1.00, P 5 .97) 11 but are no longer statistically significant for syncope. The current analyses add depth and detail, with a focus on risks of the intervention in older adults. Although older age was associated with greater risk of an SAE involving syncope, hypotension, and falls, there was no evidence of different risk associated with intensive treatment in older and younger adults. These results should reassure clinicians that treating individuals aged 75 and older to a SBP goal of less than 120 mmHg does not result in greater risk of SAEs involving syncope, hypotension, or falls than in people aged 50 to 74, although the small number of cases of syncope (n 5 14) and hypotension (n 5 7) in those aged 85 and older make those results less certain. We also identified baseline risk factors for SAEs involving syncope, hypotension, and falls, most of which are biologically plausible. Self-reported dizziness upon standing was not associated with any of these three SAE types, although confirmed orthostatic hypotension at baseline was a risk factor for future SAEs involving falls. Even though orthostatic hypotension was a risk factor for a future SAE involving a fall, the relative risk of intensive BP treatment on falls, syncope, and hypotension events was not greater for participants with baseline orthostatic hypotension than for those without.
An SAE involving syncope, hypotension, or falls occurred in approximately 2% of participants in the intensive arm. Comparing our results with those of other hypertension treatment trials is difficult because of differences in what or how SAEs were reported, but rates of relevant SAEs and risks of the intensive intervention appear similar to those reported in other hypertension trials. For example, in the Systolic Hypertension in the Elderly Program, syncope occurred in 2.2% of participants treated to a SBP less than 150 mmHg, versus 1.3% in the placebo group. 19 In the Secondary Prevention of Small Subcortical Strokes Trial, SAEs related to hypotension occurred in 1.5% of participants in the intensive arm (SBP goal <130 mm Hg) and 1.0% of those in the standard arm Model 1 (N 5 9,344) includes age, treatment group, and demographic factors (sex, race, education). Model 2 (N 5 8,778) includes age, treatment group, demographic factors, and health conditions (cardiovascular disease history, chronic kidney disease, body mass index category, alcohol use, being frail). Model 3 (N 5 7,872) includes age, treatment group, demographic factors, health conditions, and baseline measurements (systolic blood pressure; heart rate; orthostatic hypotension; dizziness; number of blood pressure medications; and use of beta-blockers, diuretics, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, alpha-blockers, nitrates, digoxin).
a As a continuous variable; hazard ratios (HRs) for age are for each standard deviation of age (9.4 years). CI 5 confidence interval.
( 20) . 20 The CI overlaps the SPRINT CI for SAE related to hypotension. Finally, the Action to Control Cardiovascular Risk in Diabetes-Blood Pressure trial also found no greater risk of falls (or fractures) in the intensive arm (SBP goal <120 mmHg) than in the standard BP group (relative risk 5 0.84, 95% CI 5 0.54-1.29, P 5 .43). 9 The SPRINT design provided several important strengths for this analysis. We rigorously collected, classified, and reported SAEs associated with syncope, hypotension, or a fall because these events are of particular interest to clinicians and patients. We included SAEs that involved one of these even if the syncope, hypotension, or fall was not the primary reason for the event; in many cases, other medical illnesses were the primary reason for the SAE. The rich clinical data in SPRINT allowed us to control for factors, such as frailty, that may have confounded the relationship between BP treatment and syncope, hypotension, or falls in prior observational studies. Moreover, more than 2,600 persons aged 75 and older participated in SPRINT, providing substantial power to detect important differences in treatment effects in older and younger adults. That said, because the trial was stopped early, the statistical power to examine some interactions and outcomes may have been diminished.
Nonetheless, we acknowledge several methodological considerations that affect interpretation of our results, the most important of which may be ascertainment bias. SAEs involving syncope, hypotension, and falls may have been overreported in the intensive treatment group. Although information on other SPRINT outcomes was collected only at quarterly visits, to reduce the potential for reporting bias, SAEs could be reported at any visit or ascertained in other ways. Because the intensive treatment group had approximately 30% more as-needed study visits than the control group, they had more opportunities to report adverse events and may have been motivated to do so because they were not blinded to treatment assignment, and risks of these events were specifically highlighted in the consent form. Another methodological consideration is that participants were monitored closely, including annual orthostatic BP measurements, and medications were adjusted as needed according to site clinician judgment. In addition, although participants with orthostatic hypotension were included, those with standing SBP less than 110 mmHg at baseline were excluded. Thus, risk of SAEs may be greater in individuals who are less carefully screened and closely monitored. Finally, we did not have information on every possible baseline characteristic that may be of interest to clinicians, and the baseline predictors we identified may be hard to use clinically. Although they identify individuals at high risk of these SAEs, they also identify individuals at high risk of cardiovascular events who may also benefit more from the intervention. 12 
CONCLUSION
Of three conceptually related, common concerns about risks of intensive BP treatment-syncope, hypotension, and falls-only hypotension was more common in participants randomized to intensive treatment. Although older age was associated with greater absolute risk of SAEs involving syncope, hypotension, and falls, the relative risks of the SPRINT intervention for older participants were not different from those for younger participants; nor for those with frailty or orthostatic hypotension compared to those participants without.
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